Mode of spironolactone anti-androgenic action: inhibition of androstanolone binding to rat prostate androgen receptor.
D000726:Androgen Antagonists; D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D003534:Cyproterone / Q000494:pharmacology; D003600:Cytosol / Q000378:metabolism; D013196:Dihydrotestosterone / Q000378:metabolism*; D004963:Estrenes / Q000494:pharmacology; D006914:Hydroxysteroids / Q000494:pharmacology; D066298:In Vitro Techniques; D007664:Ketosteroids / Q000494:pharmacology; D008297:Male; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D011956:Receptors, Cell Surface; D013148:Spironolactone / Q000494:pharmacology*; D013739:Testosterone / Q000378:metabolism
D000726:Androgen Antagonists; D004963:Estrenes; D006914:Hydroxysteroids; D007664:Ketosteroids; D011956:Receptors, Cell Surface; D013196:Dihydrotestosterone; D013148:Spironolactone; D013739:Testosterone; D003534:Cyproterone